Posted by Michael Wonder on 10 Jan 2020
Blueprint Medicines initiates rolling NDA submission to FDA for pralsetinib for the treatment of patients with RET fusion positive non-small cell lung cancer
8 January 2020 - Expect to complete NDA rolling submission for RET fusion-positive non-small cell lung cancer in Q1 2020.
Blueprint Medicines has announced it has initiated the submission of a rolling new drug application to the U.S. FDA for pralsetinib for the treatment of patients with RET fusion-positive non-small cell lung cancer. The company expects to complete the NDA submission in the first quarter of 2020.
Blueprint Medicines also plans to submit an NDA to the FDA for pralsetinib for the treatment of patients with medullary thyroid cancer previously treated with an approved multi-kinase inhibitor in the second quarter of 2020.
